37° Partly Cloudy

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
News
- Local News
- State News
Sports
- Local Sports
- Pro Sports
Lifestyle
- Local Entertainment
Multimedia
Community Choice
Features
Classifieds
- Place Ad
- Legal Notices
Public Notices
Obituaries
E-Edition

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

AstraZeneca reinforces commitment to advancing science for patients with chronic kidney disease and hyperkalemia at NKF Spring Clinical Meeting 2023

April 11, 2023

From AstraZeneca

Via Business Wire

AstraZeneca PLC (NASDAQ: AZN) Climbs to New 52-Week High

April 06, 2023

Via Investor Brand Network

Astrazeneca Plc (NASDAQ: AZN) Highlighted for Surprising Price Action

April 05, 2023

Via Investor Brand Network

Sanofi, Regeneron Shares Pop On Big News About COPD Treatment

March 27, 2023

Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade.

Via MarketBeat

Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks

March 27, 2023

From AstraZeneca

Via Business Wire

Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb

March 14, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival...

Via FinancialNewsMedia

TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

March 09, 2023

From AstraZeneca

Via Business Wire

IMFINZI significantly improved event-free survival in AEGEAN Phase III trial for patients with resectable non-small cell lung cancer

March 09, 2023

From AstraZeneca

Via Business Wire

Schrodinger is an AI-Powered Drug Discovery Developer to Watch

March 08, 2023

Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117

Via MarketBeat

Topics Artificial Intelligence

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial

March 06, 2023

From AstraZeneca

Via Business Wire

Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023

March 02, 2023

From AstraZeneca

Via Business Wire

Analysts Holding As Pfizer Waits On Two Phase 3 Studies

February 24, 2023

Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value.

Via MarketBeat

Topics Bankruptcy

Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029

February 22, 2023

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END

Via FinancialNewsMedia

Johnson & Johnson: Taking The Bull By The Horns?

February 21, 2023

Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions.

Via MarketBeat

Topics Intellectual Property Regulatory Compliance

AstraZeneca and Merck present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium

February 16, 2023

From AstraZeneca

Via Business Wire

There's a Lot to Love About Mineralys' Valentine's Day IPO

February 13, 2023

MLYS added 20% more shares to IPO funding, which goes live on 2/14. The bump secured liquidity to stabilize development, improving market cap to $683 million

Via MarketBeat

Topics Initial Public Offering

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aiming to Capture Significant Market Share for Treatment and Prevention of COVID-19 Illness with Innovative Inhaled NanoAb

February 06, 2023

Via Investor Brand Network

TEZSPIRE® approved for self-administration in the US with a new pre-filled pen

February 02, 2023

From AstraZeneca

Via Business Wire

These 2 Healthcare Stocks Have Doubled in 2023

February 01, 2023

Wouldn’t it be great if a stock had a bulkier capitalization and 2x potential? This is rare but possible for these two small-mid health care stocks.

Via MarketBeat

Cassava Sciences Stock Undervalued with Its $124 Price Target?

January 30, 2023

Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a

Via MarketBeat

Mergers and Acquisitions in 2023 Off To A Strong Start

January 26, 2023

Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.

Via MarketBeat

AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.

January 23, 2023

From AstraZeneca

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)

January 20, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials

January 19, 2023

EQNX::TICKER_START (NASDAQ:TCBP),(NASDAQ:CRDF),(NASDAQ:CYAD),(NASDAQ:RIGL),(NASDAQ:AZN) EQNX::TICKER_END

Via FinancialNewsMedia

AbbVie Stock: Dividend King ABBV Overview

January 19, 2023

Via MarketBeat

HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China

January 18, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?

January 18, 2023

Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.

Via MarketBeat

Topics Stocks

AIRSUPRA™ (PT027) approved in the US for asthma

January 11, 2023

From AstraZeneca

Via Business Wire

January 10, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

CinCor Pharma (NASDAQ: CINC) Enters Into Agreement to be Acquired by AstraZeneca (NASDAQ: AZN) for $1.3 Billion

January 09, 2023

CinCor Pharma, Inc. (NASDAQ: CINC) is a clinical-stage biopharmaceutical company, which is focused on the research and development of treatments

Via Spotlight Growth

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Multimedia
Local Events
Classifieds
Obituaries
Weather
Online Features

Services

About Us
Contact Us
Promote Your Event
Subscriber Services
Online Forms
Rack Locations

woonsocketcall.com
Address: 154 Main Street
Woonsocket, RI 02895
Phone: 401-762-3000
Email: notices@woonsocketcall.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

Press Releases about AstraZeneca PLC - American Depositary Shares

Sections

Services